Celcuity Inc. (CELC)
$
101.16
+2.00 (1.98%)
Key metrics
Financial statements
Free cash flow per share
0.1750
Market cap
4.6 Billion
Price to sales ratio
16.9 Thousand
Debt to equity
2.7389
Current ratio
12.2576
Income quality
-0.0496
Average inventory
0
ROE
-1.7900
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Celcuity Inc., a clinical stage biotechnology company focused on developing molecularly targeted therapies for cancer patients in the United States, reported an income before tax of -$111,779,105.00 showcasing its pre-tax profitability. Despite this positive indication, the company reported a net loss of -$111,779,105.00 indicating challenges in its operations. The earnings per share (EPS) is reported at -$2.83 which highlights the company's profitability on a per-share basis. Additionally, the company reported depreciation and amortization expenses of $129,947.00 reflecting the wear and tear of its assets. The income before tax ratio stands at 0.00 reflecting the pre-tax margin. Celcuity's CELsignia diagnostic platform allows for the identification of specific abnormal cellular processes in patients’ cancer using their living tumor cells, enabling targeted therapy selection. Among its drug candidates, Gedatolisib selectively targets various class I isoforms of PI3K and mammalian target of rapamycin, particularly focusing on hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also advancing the CELsignia MP test, a qualitative laboratory-developed test to measure HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Furthermore, Celcuity has a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Founded in 2011 and headquartered in Minneapolis, Minnesota, the company operates within a crucial and transformative landscape of cancer treatment. In terms of its market positioning, the stock is affordable at $51.88 making it suitable for budget-conscious investors. With a low average trading volume of 1,141,531.00 the stock indicates lower market activity, suggesting a potentially less volatile investment environment. With a market capitalization of $4,680,725,399.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor shaping the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth, providing promising avenues for investment as it continues to develop its targeted therapies and diagnostic platforms.
Is Celcuity Inc. (CELC) a good investment?
Investing in Celcuity Inc. (CELC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Celcuity Inc. (CELC)'s stock forecast?
Analysts predict Celcuity Inc. stock to fluctuate between $7.58 (low) and $112.64 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Celcuity Inc.'s market capitalization?
As of 2025-12-19, Celcuity Inc.'s market cap is $4,680,725,399, based on 46,270,516 outstanding shares.
How does Celcuity Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Celcuity Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Celcuity Inc. (CELC) stock?
To buy Celcuity Inc. (CELC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CELC. Place an order (Market, Limit, etc.).
What is the best time to invest in Celcuity Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Celcuity Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.83 | Growth: 5.20%.
Where can I find Celcuity Inc.'s investor relations reports?
Visit https://www.celcuity.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Celcuity Inc.?
You can explore historical data from here
What is the all-time high and low for Celcuity Inc. stock?
All-time high: $112.64 (2025-12-12) | All-time low: $4.81 (2022-05-17).
What are the key trends affecting Celcuity Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA wild-type (“WT”), advanced breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. The additional study results were presented in an oral presentation session at the 2025 San Antonio Breast Cancer Symposium (“SABCS”) today, Thursday, December 11.
marketbeat.com
Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.
fool.com
A top biotech fund just made a bold move while Celcuity trades near record highs—here's what they might see coming next.
fool.com
New York City-based Apis Capital Advisors added 776,000 shares in CELC during the third quarter, establishing a position valued at $38.3 million. The new stake represents 8.5% of Apis' reportable assets under management at quarter-end.
seekingalpha.com
Celcuity has transitioned from a speculative biotech to a de-risked pre-commercial firm, driven by unprecedented Phase 3 VIKTORIA-1 trial results. Celcuity's gedatolisib demonstrated significant efficacy and a favorable safety profile in HR+/HER2- advanced breast cancer, supporting a strong investment thesis. With a completed NDA under the FDA's RTOR program and a $455M cash position, CELC is well-funded for commercialization and pipeline expansion.
fool.com
New York City-based Apis Capital Advisors added 776,000 shares in CELC during the third quarter, establishing a position valued at $38.3 million. The new stake represents 8.5% of Apis' reportable assets under management at quarter-end.
globenewswire.com
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data.
globenewswire.com
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025.
globenewswire.com
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”). The NDA was submitted under the FDA's Real-Time Oncology Review (“RTOR”) program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on promising preliminary clinical data. The submission is based on clinical data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial.
defenseworld.net
Celcuity, Inc. (NASDAQ: CELC - Get Free Report)'s share price rose 8.1% during mid-day trading on Friday after Craig Hallum raised their price target on the stock from $96.00 to $108.00. Craig Hallum currently has a buy rating on the stock. Celcuity traded as high as $93.04 and last traded at $92.9760. Approximately 696,304 shares traded
See all news
